Nectar Lifesciences Ltd. logo

Nectar Lifesciences Ltd. (NECLIFE)

Market Closed
7 Aug, 22:00
MSE MSE
10. 60
+0.21
+2.0212%
- Market Cap
- P/E Ratio
0.2% Div Yield
1,565 Volume
- Eps
10.39
Previous Close
Add Transaction
Day Range
10.51 10.69
Year Range
9.2 22.49
Want to track NECLIFE and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

NECLIFE closed Friday higher at ₹10.6, an increase of 2.0212% from Thursday's close, completing a monthly decrease of -5.945% or -₹0.67. Over the past 12 months, NECLIFE stock lost -46.8672%.
NECLIFE is not paying dividends to its shareholders.
The last earnings report, released on May 28, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -2.404%, based on the last three reports.
Nectar Lifesciences Ltd. has completed 1 stock splits, with the recent split occurring on Nov 12, 2008.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XNSE (INR).

NECLIFE Chart

Nectar Lifesciences Ltd. (NECLIFE) FAQ

What is the stock price today?

The current price is ₹10.60.

On which exchange is it traded?

Nectar Lifesciences Ltd. is listed on MSE.

What is its stock symbol?

The ticker symbol is NECLIFE.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.2%.

What is its market cap?

As of today, no market cap data is available.

Has Nectar Lifesciences Ltd. ever had a stock split?

Nectar Lifesciences Ltd. had 1 splits and the recent split was on Nov 12, 2008.

Nectar Lifesciences Ltd. Profile

Specialty Retail Industry
Consumer Discretionary Sector
- CEO
MSE Exchange
INE023H01027 ISIN
India Country
1,686 Employees
18 Sep 2020 Last Dividend
12 Nov 2008 Last Split
- IPO Date

Overview

Nectar Lifesciences Limited is a prominent entity in the pharmaceutical domain, engaged in the manufacture and sale of a broad range of pharmaceutical products across India and the international market. Established in 1995 and with its headquarters in Chandigarh, India, the company has grown to be a key player in the pharmaceutical industry. It specializes in producing active pharmaceutical ingredients (APIs) and intermediates, alongside offering contract manufacturing services for finished dosage forms. The company's commitment to quality and innovation has positioned it as a trusted partner in the healthcare sector worldwide.

Products and Services

Active Pharmaceutical Ingredients (APIs) and Intermediates: Nectar Lifesciences Limited boasts a comprehensive portfolio of APIs and intermediates, including cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. These high-quality components are crucial for the formulation of various antibiotics and cephalosporins, catering to a vast array of therapeutic needs.

Contract Manufacturing for Finished Dosage Forms: The company extends its expertise to the manufacture of finished dosage forms under contract. This includes a range of pharmaceutical formulations such as tablets, capsules, dry powder oral suspensions, granules, and injectables specifically for cephalosporins. Such services highlight the company’s flexibility and capability to meet diverse customer requirements in the pharmaceutical industry.

Menthol and Pearl Capsules: Beyond their core pharmaceutical products and services, Nectar Lifesciences Limited also offers menthol and pearl capsules. These products stand as a testament to the company’s diversification and innovation in exploring various segments of the healthcare and wellness market.

Contact Information

Address: SCO 38-39
Phone: 91 17 2504 7915